文献速递胸部肿瘤

阿法替尼对比化疗治疗携带罕见表皮生长因子受体突变非小细胞肺癌患者的实用性随机研究:ACHILLES/TORG1834

Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With Non-Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations: ACHILLES/TORG1834.
PubMed 文献 · J Clin Oncol · 2025-04-16

ACHILLES/TORG1834是首个在携带罕见EGFR突变(排除外显子20插入和T790M)的初治非鳞非小细胞肺癌患者中比较阿法替尼与铂类联合培美曲塞化疗的随机开放标签研究,在51家日本机构纳入109例患者,中期分析显示阿法替尼组中位无进展生存期显著延长(10.6个月 vs 5.7个月;HR 0.421;P=0.0010),数据与安全监察委员会建议提前终止研究。

要点

  • 阿法替尼组中位PFS为10.6个月,化疗组为5.7个月,HR 0.421(95%CI 0.251-0.706),P=0.0010。
  • 阿法替尼总体客观缓解率为61.7%,主要罕见突变、复合突变和其他突变分别为55.8%、72.7%和60.0%。
  • 阿法替尼常见≥3级不良事件为腹泻、甲沟炎和皮疹;化疗为食欲减退和恶心。

核心结论

  • 作者结论认为,阿法替尼应被视为携带致敏性罕见EGFR突变非小细胞肺癌患者的标准初始治疗。

研究设计与样本

  • 随机、开放标签研究,在51家日本机构开展,纳入初治非鳞非小细胞肺癌且携带罕见EGFR突变(排除外显子20插入和T790M突变)的患者。
  • 患者按2:1随机分配接受阿法替尼(30或40 mg口服,由主治医师决定)或铂类(顺铂或卡铂)联合培美曲塞化疗序贯培美曲塞维持治疗。
  • 主要终点为无进展生存期(PFS),次要终点包括客观缓解率(ORR)、总生存期和安全性;预设中期分析以便及时提供有临床意义的信息,必要时给出交叉推荐。
  • 2019年3月至2023年2月共纳入109例患者;中期分析中数据与安全监察委员会建议提前终止研究。

主要发现

  • 阿法替尼组中位PFS为10.6个月,化疗组为5.7个月,风险比0.421(95%CI 0.251-0.706),P=0.0010,阿法替尼组显著更长。
  • 阿法替尼总体客观缓解率为61.7%,主要罕见突变(G719X、L861Q和S768I)为55.8%,复合突变为72.7%,其他突变为60.0%。
  • 阿法替尼最常见的≥3级不良事件为腹泻、甲沟炎和皮疹;化疗为食欲减退和恶心。

关键数值与推荐

  • 阿法替尼给药剂量为30或40 mg口服,由主治医师决定。
  • 患者按2:1随机分配至阿法替尼组或铂类联合培美曲塞化疗组。

临床怎么用

  • 作者结论认为,阿法替尼应被视为携带致敏性罕见EGFR突变非小细胞肺癌患者的标准初始治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To our knowledge, the ACHILLES/TORG1834 trial is the first randomized study comparing afatinib and chemotherapy in patients with non-small cell lung cancer (NSCLC) harboring sensitizing uncommon epidermal growth factor receptor (EGFR) mutations. METHODS: This randomized, open-label study was performed at 51 Japanese institutions and recruited treatment-naïve patients with nonsquamous NSCLC with uncommon EGFR mutations, excluding exon 20 insertions and T790M mutations. Patients were randomly assigned 2:1 to receive afatinib (30 or 40 mg orally, at the treating physician's discretion) or a combination of platinum (cisplatin or carboplatin) and pemetrexed, followed by pemetrexed maintenance. The primary end point was progression-free survival (PFS). Secondary end points included objective response rate (ORR), overall survival, and safety. A prespecified interim analysis was planned to provide clinically meaningful information promptly, along with a crossover recommendation if necessary. RESULTS: A total of 109 patients were enrolled between March 2019 and February 2023. In the interim analysis, the Data and Safety Monitoring Committee recommended early study termination. The median PFS was significantly longer in patients receiving afatinib than in those undergoing chemotherapy (10.6 v 5.7 months; hazard ratio, 0.421 [95% CI, 0.251 to 0.706]; P = .0010). ORRs to afatinib were similar across the overall population and among participants with major uncommon (G719X, L861Q, and S768I), compound, and other mutations (61.7%, 55.8%, 72.7%, and 60.0%, respectively). The most common grade 3 or higher adverse events were diarrhea, paronychia, and rash for afatinib, and appetite loss and nausea for chemotherapy. CONCLUSION: Afatinib should be considered the standard initial therapy for patients with NSCLC with sensitizing uncommon EGFR mutations.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Miura S, Tanaka H, Misumi T, et al. Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With Non-Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations: ACHILLES/TORG1834. J Clin Oncol. 2025. PMID: 40239133. doi:10.1200/JCO-24-02007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。